Effect of a peroxisome proliferator-activated receptor γ sumoylation mutant on neointimal formation after balloon injury in rats

Atherosclerosis

Volumn 206, Issue 2, 2009, Pages 411-417

  Lim, Soo ^a,b   Ahn, Byung Yong ^a   Chung, Sung Soo ^a   Park, Ho Seon ^a   Cho, Bong Jun ^a,b   Kim, Min ^a   Choi, Sung Hee ^a,b   Lee, In Kyu ^c   Lee, Sang Won ^d   Choi, Soo Joon ^e   Chung, Chin Ha ^e   Cho, Young Min ^a   Lee, Hong Kyu ^a   Park, Kyong Soo ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Kyungpook National University School of Medicine   (South Korea)

^d Korea University   (South Korea)

^e Seoul National University   (South Korea)

Author keywords

Apoptosis; Neointima; PPAR ; Proliferation; Sumoylation; Vascular smooth muscle

Indexed keywords

ADENOVIRUS VECTOR; CASPASE 3; CELL NUCLEUS RECEPTOR; GREEN FLUORESCENT PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SUMO PROTEIN;

ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY INJURY; ARTERY INTIMA; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY INJURY; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN 3T3; CONTROLLED STUDY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; INHIBITION KINETICS; INSULIN SENSITIVITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; RAT; SMOOTH MUSCLE FIBER; SUMOYLATION; VASCULAR SMOOTH MUSCLE; VIRAL GENE DELIVERY SYSTEM; WILD TYPE;

ANIMALS; BALLOON DILATION; CAROTID ARTERIES; CAROTID ARTERY INJURIES; CELL PROLIFERATION; MICE; MUSCLE, SMOOTH, VASCULAR; NIH 3T3 CELLS; PPAR GAMMA; RATS; SUMO-1 PROTEIN; TUNICA INTIMA; TUNICA MEDIA;

EID: 70349414652     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.02.031     Document Type: Article

References (34)

1. Hsueh W.A., Jackson S., and Law R.E. Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care 24 (2001) 392-397
2. Law R.E., Goetze S., Xi X.P., et al. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 101 (2000) 1311-1318
3. Blanquart C., Barbier O., Fruchart J.C., Staels B., and Glineur C. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol 85 (2003) 267-273
4. Phillips J.W., Barringhaus K.G., Sanders J.M., et al. Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes. Circulation 108 (2003) 1994-1999
5. Choi D., Kim S.K., Choi S.H., et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 27 (2004) 2654-2660
6. Lim S., Jin C.J., Kim M., et al. PPARgamma gene transfer sustains apoptosis, inhibits vascular smooth muscle cell proliferation, and reduces neointima formation after balloon injury in rats. Arterioscler Thromb Vasc Biol 26 (2006) 808-813
7. Ohshima T., Koga H., and Shimotohno K. Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification. J Biol Chem 279 (2004) 29551-29557
8. Yamashita D., Yamaguchi T., Shimizu M., et al. The transactivating function of peroxisome proliferator-activated receptor gamma is negatively regulated by SUMO conjugation in the amino-terminal domain. Genes Cells 9 (2004) 1017-1029
9. Pascual G., Fong A.L., Ogawa S., et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437 (2005) 759-763
10. Wilson V.G., and Rangasamy D. Intracellular targeting of proteins by sumoylation. Exp Cell Res 271 (2001) 57-65
11. Hay R.T. SUMO: a history of modification. Mol Cell 18 (2005) 1-12
12. Rodriguez M.S., Dargemont C., and Hay R.T. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J Biol Chem 276 (2001) 12654-12659
13. Melchior F. SUMO-nonclassical ubiquitin. Annu Rev Cell Dev Biol 16 (2000) 591-626
14. Kim J., Cantwell C.A., Johnson P.F., Pfarr C.M., and Williams S.C. Transcriptional activity of CCAAT/enhancer-binding proteins is controlled by a conserved inhibitory domain that is a target for sumoylation. J Biol Chem 277 (2002) 38037-38044
15. Hirano Y., Murata S., Tanaka K., Shimizu M., and Sato R. Sterol regulatory element-binding proteins are negatively regulated through SUMO-1 modification independent of the ubiquitin/26 S proteasome pathway. J Biol Chem 278 (2003) 16809-16819
16. Eloranta J.J., and Hurst H.C. Transcription factor AP-2 interacts with the SUMO-conjugating enzyme UBC9 and is sumolated in vivo. J Biol Chem 277 (2002) 30798-30804
17. Rangwala S.M., Rhoades B., Shapiro J.S., et al. Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity. Dev Cell 5 (2003) 657-663
18. Hong H.K., Cho Y.M., Park K.H., et al. Peroxisome proliferator-activated receptor gamma mediated inhibition of plasminogen activator inhibitor type 1 production and proliferation of human umbilical vein endothelial cells. Diabetes Res Clin Pract 62 (2003) 1-8
19. Choi S.J., Chung S.S., Rho E.J., et al. Negative modulation of RXRalpha transcriptional activity by small ubiquitin-related modifier (SUMO) modification and its reversal by SUMO-specific protease SUSP1. J Biol Chem 281 (2006) 30669-30677
20. Ansari B., Coates P.J., Greenstein B.D., and Hall P.A. In situ end-labelling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol 170 (1993) 1-8
21. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., and Evans R.M. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93 (1998) 241-252
22. Li A.C., Brown K.K., Silvestre M.J., et al. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106 (2000) 523-531
23. Collins A.R., Meehan W.P., Kintscher U., et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 21 (2001) 365-371
24. Bruemmer D., Yin F., Liu J., et al. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells. Circ Res 93 (2003) e38-e47
25. Bishop-Bailey D., Hla T., and Warner T.D. Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptor-gamma ligand therapy. Circ Res 91 (2002) 210-217
26. Marx N., Schonbeck U., Lazar M.A., Libby P., and Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 83 (1998) 1097-1103
27. Miwa Y., Sasaguri T., Inoue H., et al. 15-Deoxy-Delta(12,14)-prostaglandin J(2) induces G(1) arrest and differentiation marker expression in vascular smooth muscle cells. Mol Pharmacol 58 (2000) 837-844
28. Bruemmer D., Blaschke F., and Law R.E. New targets for PPARgamma in the vessel wall: implications for restenosis. Int J Obes (Lond) 29 Suppl. 1 (2005) S26-S30
29. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
30. Samaha F.F., Szapary P.O., Iqbal N., et al. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 26 (2006) 624-630
31. Ali A.A., Weinstein R.S., Stewart S.A., et al. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146 (2005) 1226-1235
32. Mudaliar S., Chang A.R., and Henry R.R. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract 9 (2003) 406-416
33. Home P.D., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 357 (2007) 28-38
34. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471